Skip to main content
TipRanks
Go Ultimate75% OFF

Solara Active Pharma Sciences Ltd. (SOLARA) AI Stock Analysis

3 Followers
IN:SOLARA

Solara Active Pharma Sciences Ltd.

(NSE:SOLARA)

Select Model
Rating:61Neutral
Price Target:INR 663.00â–²(5.51% Upside)
Action:reiterated
Date:09/08/26

Solara's overall score of 61 is driven primarily by exceptionally strong technical momentum, heavily offset by poor profitability and valuation metrics. While the stock's price trends are robust and trading well above major moving averages, the underlying fundamentals present significant long-term risks, highlighted by deeply negative earnings, contracting gross margins, and a steep decline in cash flows.

Positive Factors
Revenue Growth RecoveryThe return to 13.5% revenue growth indicates that Solara regained commercial momentum after a flat FY2025. Sustained growth would improve fixed-cost absorption, support capacity utilization, and provide a stronger base for rebuilding profitability across future periods.
Negative Factors
Persistent Net LossThe FY2026 net loss shows that revenue recovery has not yet translated into sustainable bottom-line profitability. Continued losses can constrain internally generated capital, weaken shareholder returns, and leave Solara more exposed to any further deterioration in operating conditions.

Solara Active Pharma Sciences Ltd. (SOLARA) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%40%50%IN:SOLARA+19.89%INDA-2.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 30.20B
Dividend Yield
―
Average Volume (3M)
22.68K
Price to Earnings (P/E)
81.4
Beta (1Y)
0.62
Revenue Growth
27.30%
EPS Growth
456.80%
Country
India
Employees
1,669
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Solara Active Pharma Sciences Ltd. Business Overview & Revenue Model

Company Description

Solara Active Pharma Sciences Limited is an Indian-based pharmaceutical company primarily involved in the comprehensive development, production, and global trade of active pharmaceutical ingredients (APIs). Their activities span the manufacturing, pr...

How the Company Makes Money

Solara makes money primarily by manufacturing and selling active pharmaceutical ingredients (APIs) to pharmaceutical companies that formulate and commercialize finished drug products. Revenue is generated from (1) API sales, where Solara supplies spe...

Solara Active Pharma Sciences Ltd. Financial Statement Overview

Summary

Financials reflect a mixed turnaround effort. Despite solid revenue growth and a healthier balance sheet driven by aggressive debt reduction, the company struggles with severely contracting margins, recurring net losses, and sharply declining free cash flow.

Income Statement

42Neutral

Balance Sheet

68Positive

Cash Flow

58Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue15.35B13.69B12.84B12.89B14.27B12.68B
Gross Profit4.12B3.66B6.57B-1.30B1.25B5.60B
EBITDA2.35B1.87B2.06B-2.82B1.53B863.30M
Net Income369.40M-74.10M5.40M-5.67B-221.70M-581.50M
Balance Sheet
Total Assets24.54B23.33B22.32B23.51B28.99B29.53B
Cash, Cash Equivalents and Short-Term Investments709.10M533.40M41.10M84.40M87.30M463.80M
Total Debt5.91B6.87B7.96B10.12B10.13B10.37B
Total Liabilities10.15B10.77B11.35B14.14B13.97B14.18B
Stockholders Equity14.36B12.53B10.94B9.34B15.00B15.25B
Cash Flow
Free Cash Flow088.80M1.73B678.10M449.40M-4.51B
Operating Cash Flow0617.00M2.13B1.09B1.56B-2.42B
Investing Cash Flow0-998.60M-368.30M-35.10M-811.40M-2.43B
Financing Cash Flow0386.90M-1.80B-1.06B-1.13B3.34B

Solara Active Pharma Sciences Ltd. Technical Analysis

Technical Analysis SentimentNeutral
Last Price628.40

Price Trends

50DMA677.06Negative
100DMA620.38Positive
200DMA562.87Positive

Market Momentum

MACD-3.84Positive
RSI44.36Neutral
STOCH16.30Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SOLARA, the sentiment is Neutral. The current price of 628.40 is below the 20-day moving average (MA) of 645.66, below the 50-day MA of 677.06, and above the 200-day MA of 562.87, indicating a neutral trend. The MACD of -3.84 indicates Positive momentum. The RSI at 44.36 is Neutral, neither overbought nor oversold. The STOCH value of 16.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SOLARA.

Solara Active Pharma Sciences Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:SOLARA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:STARIN:STAR74OutperformINR 89.66B14.46―0.52%11.28%55.18%
IN:IOLCPIN:IOLCP72OutperformINR 56.27B26.61―0.54%26.76%75.41%
IN:UNICHEMLABIN:UNICHEMLAB63NeutralINR 33.80B9.74――6.44%283.10%
IN:SOLARAIN:SOLARA61NeutralINR 30.74B81.38――27.30%456.80%
IN:GRANULESIN:GRANULES59NeutralINR 199.33B28.46―0.21%21.75%36.70%
IN:HIKALIN:HIKAL56NeutralINR 27.35B-551.90―0.27%8.93%-149.51%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%IN:SOLARAIN:GRANULESIN:HIKALIN:IOLCPIN:STARIN:UNICHEMLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:SOLARA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:SOLARASolara Active Pharma Sciences Ltd.628.40106.0520.30%
IN:GRANULESGranules India Limited823.70292.2154.98%
IN:HIKALHikal Limited220.352.721.25%
IN:IOLCPIOL Chemicals & Pharmaceuticals Ltd.184.1092.53101.05%
IN:STARStrides Pharma Science Ltd964.9080.149.06%
IN:UNICHEMLABUnichem Laboratories Limited469.5514.553.20%

Solara Active Pharma Sciences Ltd. Corporate Events

Solara Tightens KYC Norms for Physical Shareholders Under SEBI Mandate

Sep 26, 2026

Solara Active Pharma Sciences Ltd., a listed pharmaceutical company specializing in active pharmaceutical ingredients, is tightening compliance for investors who still hold shares in physical form. The move reflects broader regulatory efforts in Indi...

Solara Active Pharma Files Sustainability Report for FY 2025-26

Aug 25, 2026

Solara Active Pharma Sciences Limited has submitted its Business Responsibility and Sustainability Report for the 2025-26 financial year, covering operations from April 1, 2025 to March 31, 2026. The report is filed under SEBI’s listing regulations a...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 08, 2026